Page 21 - Pharma Sector

GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion

Lawsuits against the companies began piling up in both state and federal courts after the US Food and Drug Administration in 2020 asked manufacturers to pull Zantac off the market

Policy support important as India largely an out-of-pocket market: Panchal

AstraZeneca Pharma India Managing Director and Country President, Sanjeev Panchal, talks to Shine Jacob about the company's future plans in an interview

Shilpa Medicare shares rise 3% on receiving CEP for Desmopressin; details

Shilpa Medicare share price surged after the company said that its arm, Shilpa Pharma Lifesciences, has received certificate of suitability (CEP) from EDQM for API, Desmopressin

Biocon Biologics refinances $1.1 bn debt through bonds, syndicated facility

Refinancing will improve liquidity and help in reinvestment, says company

Alembic Pharma share price gains 5% after USFDA okays seizures drug

Alembic Pharma share price surged after the United States Food and Drug Administration (USFDA) gave final approval for Lamotrigine ExtendedRelease Tablets USP, 200 mg, 250 mg, and 300 mg.

Packaged-food makers now targeting Ozempic users with new product line

While the food industry has never met a diet trend it didn't seek to capitalize on, GLP-1s at one point seemed to present an existential threat: the disappearance of cravings

Royal Philips' 1st female top executive in 133-yr history begins her tenure

Charlotte Hanneman, 45, is taking over as the CFO of the Dutch maker of medical equipment, succeeding Abhijit Bhattacharya

Fake medicines pose health risks, economic costs; India fails to act

This attitude will need to change if India is serious about escaping the middle-income trap and joining the ranks of high-income nations - even three or four decades from now

Indian pharma companies set to see 9-11% growth in FY25, says Icra

The domestic market is expected to see a positive turnaround, with ICRA projecting revenue growth of 7-9 per cent for its sample set of companies in FY25

What drove this pharmaceutical stock's 4% increase today? Find out here!

Alembic Pharma share price surged after the USFDA issued establishment inspection report (EIR) for the inspection carried out at the company's Oral Solid Formulation Facility (F-I).

Lupin share falls over 2% as USFDA issues 3 observations for Pithampur unit

Lupin share price fell after the United States Food and Drug Administration (USFDA) issued 3 observations for its Pithampur Unit-1, based in Madhya Pradesh.

SeQuent Scientific jumps 18% after announcing merger with Viyash Life

The company said the proposed merger is expected to be Ebitda margin accretive and deleverage SeQuent's balance sheet.fle

CDSCO flags over 50 drugs of various companies as 'not of standard quality'

The country's central drug regulatory authority has listed samples of more than 50 drugs, including paracetamol, Pan D, calcium and vitamin D3 supplements, and anti-diabetes pills, as "not of standard quality" in its latest report. The batches of medicines flagged by the Central Drugs Standard Control Organisation (CDSCO) in its drug alert for August are of companies such as Alkem Laboratories, Hindustan Antibiotics Limited, Hetero Labs Limited, Karnataka Antibiotics and Pharmaceuticals Ltd, Nestor Pharmaceuticals Ltd, Priya Pharmaceuticals and Scott-Edil Pharmacia Ltd. The CDSCO's drug alert for August included samples from batches of medications such as Shelcal, Vitamin B Complex with Vitamin C Softgels, vitamin C and D3 tablets and Ciprofloxacin tablets. High blood pressure medications Telmisartan and Atropine Sulphate and antibiotics such as Amoxicillin And Potassium Clavulanate tablets have also been categorised as not of "not of standard quality". While batches of some drugs

Price hikes improve margins for diagnostic labs amid online competition

Diagnostic companies like Metropolis Healthcare and Dr Lal PathLabs have implemented price hikes to cope with inflationary pressures

AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.

Medical gear makers up in arms against zero-duty imports under EU FTA

India is 70% import-dependent, and Germany and the Netherlands are among the top five countries

Pharma's power pill: A strong dose of steady pricing and new launches

Pricing pulse check: US market demand, domestic stability as growth tonics

Mankind Pharma to raise funds up to Rs 10k crore via debt instruments

The board announced the issuance of corporate guarantees for four of its subsidiaries, namely Mankind Agritech, Appian Properties, Copmed Pharmaceuticals, and Lifestar Pharma.

Panacea Biotec gets $20 mn loan from US DFC for capex; stock rises 5%

The shares of Panacea Biotec rose after the company announced that it has secured $20 million in loan from US International Development Finance Corp (DFC).

Pharma's bitter pill: Falling API prices signal Chinese predatory play

An industry expert pointed out that Chinese companies typically resort to predatory pricing whenever API production increases in India